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Abstract
Aims: To undertake a post-hoc analysis, utilizing a hypoglycaemia risk score based on
DEVOTE trial data, to investigate if a high risk of severe hypoglycaemia was associ-
ated with an increased risk of cardiovascular events, and whether reduced rates of
severe hypoglycaemia in patients identified as having the highest risk affected the
risk of cardiovascular outcomes.
Materials and Methods: The DEVOTE population was divided into quartiles
according to patients' individual hypoglycaemia risk scores. For each quartile, the
observed incidence and rate of severe hypoglycaemia, major adverse cardiovascular
event (MACE) and all-cause mortality were determined to investigate whether those
with the highest risk of hypoglycaemia were also at the greatest risk of MACE and
all-cause mortality. In addition, treatment differences within each risk quartile [insulin
degludec (degludec) vs. insulin glargine 100 units/mL (glargine U100)] in terms of
severe hypoglycaemia, MACE and all-cause mortality were investigated.
Results: Patients with the highest risk scores had the highest rates of severe
hypoglycaemia, MACE and all-cause mortality. Treatment ratios between degludec
and glargine U100 in the highest risk quartile were 95% confidence interval (CI) 0.56
(0.39; 0.80) (severe hypoglycaemia), 95% CI 0.76 (0.58; 0.99) (MACE) and 95% CI
0.77 (0.55; 1.07) (all-cause mortality).
Conclusions: The risk score demonstrated that a high risk of severe hypoglycaemia
was associated with a high incidence of MACE and all-cause mortality and that, in
this high-risk group, those treated with degludec had a lower incidence of MACE.
These observations support the hypothesis that hypoglycaemia is a risk factor for
cardiovascular events.
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1 | INTRODUCTION
Hypoglycaemia is one of the main barriers preventing optimal
glycaemic control in insulin-treated patients with diabetes.1 Although
hypoglycaemia, at all levels, is associated with a range of adverse
events, severe hypoglycaemia in particular has been linked to an
increased risk of major adverse cardiovascular events (MACE) and all-
cause mortality in patients with type 2 diabetes (T2D).1–10 Whether
the association is causal or whether hypoglycaemia identifies vulnerable
individuals that would probably suffer adverse outcomes is still
debated. One factor favouring a causal link between hypoglycaemia
and MACE is the number of plausible mechanisms whereby
hypoglycaemia could lead to adverse cardiovascular consequences.
These include changes in the electrocardiogram (T-wave inversions; ST
segment depressions; QTc prolongation), cardiac arrhythmias,
sympathoadrenal activation, changes in blood coagulation and pro-
longed low-grade inflammation with impaired endothelial function last-
ing weeks after a hypoglycaemic event.11–15 Regardless of whether
hypoglycaemia is a risk factor or a risk marker, it is important to avoid
hypoglycaemic episodes and their detrimental effects on patients.16
DEVOTE was a treat-to-target, randomized, double-blind, active-
comparator, cardiovascular outcomes trial designed to investigate the
cardiovascular safety of insulin degludec (degludec) compared with
insulin glargine 100 units/mL (glargine U100) in patients with T2D.17,18
DEVOTE demonstrated that degludec was non-inferior to glargine
U100 in terms of a three-point MACE, including cardiovascular death,
non-fatal myocardial infarction or non-fatal stroke, and was superior
with regard to hypoglycaemia risk, with lower rates of both severe and
nocturnal severe hypoglycaemia at equivalent glycaemic control.17,18
We utilized data from DEVOTE to develop a simple hypoglycaemia
risk score with sufficient accuracy to identify patients at increased risk
of experiencing severe hypoglycaemia, as well as differentiate between
those at high and low risk (as described in our companion manu-
script).19 The aim of the current study was to undertake a post-hoc
analysis utilizing the hypoglycaemia risk score to investigate if a high
risk of severe hypoglycaemia was associated with an increased risk of
cardiovascular events. Furthermore, we investigated whether a reduc-
tion in severe hypoglycaemia in patients identified as having the highest
risk impacts upon the risk of cardiovascular outcomes.
2 | MATERIALS AND METHODS
DEVOTE (ClinicalTrials.gov number NCT01959529) was a treat-to-tar-
get, randomized, double-blind, active basal insulin comparator,
cardiovascular outcomes trial designed to continue until at least
633 MACE had accrued.17,18 DEVOTE was conducted in accordance
with the Declaration of Helsinki principles and ICH Good Clinical Prac-
tice guidelines.20,21 Patients with T2D at high risk of cardiovascular
events (n = 7637) were randomized 1:1 to receive either degludec or
glargine U100 once daily, both in identical vials.
The primary endpoint in DEVOTE was defined as the time from
randomization to the first occurrence of MACE (a composite of death
from cardiovascular causes, non-fatal myocardial infarction or non-
fatal stroke). Severe hypoglycaemia was defined in accordance with
the American Diabetes Association criteria as an episode requiring the
assistance of another person to administer carbohydrate or glucagon
or to take other corrective actions actively, and was the secondary
confirmatory endpoint.22
The hypoglycaemia risk score, the development and validation of
which is described in our companion manuscript, was used to divide the
patient population into quartiles according to the patient's risk score
and arbitrarily named ‘moderate’, ‘moderately high’, ‘high’ and ‘very
high’. Factors that increased the risk of hypoglycaemia were insulin
treatment regimen, diabetes duration, female gender, age and glycated
haemoglobin (HbA1c). These quartiles were deliberately not described
as low risk, given that the trial population was mostly receiving insulin
therapy. For each risk quartile, the observed incidence and rate of
severe hypoglycaemia, MACE and all-cause mortality were determined
to investigate whether those with the highest risk of hypoglycaemia
were also at the greatest risk of MACE or all-cause mortality. This anal-
ysis was also repeated using the LEADER trial population.23
The prespecified primary models used to compare the random-
ized treatment arms in DEVOTE (a Cox proportional hazard model
and a negative binomial model) were used to investigate treatment
differences within each risk quartile (degludec vs. glargine U100) in
terms of severe hypoglycaemia, MACE and all-cause mortality.
The datasets analysed during the current study are available from
the corresponding author on request.
3 | RESULTS
The baseline characteristics across the risk quartiles are summarized
in Table 1. Notably, all quartiles had a comparable proportion of
patients with established cardiovascular disease. Glucose-lowering
efficacy was similar across the quartiles, with reductions in HbA1c of
1.0% (very high-risk quartile), 0.9% (high-risk quartile), 0.9% (moder-
ately high-risk quartile) and 0.7% (moderate risk quartile) (Table S1;
see Supporting Information). Patients in the very high-risk quartile had
the highest HbA1c levels at both baseline (8.6%) and at the end of the
trial (7.6%).
As expected, the hypoglycaemia risk score predicted a patient's risk
of severe hypoglycaemia; this was evident by comparing the rates of
hypoglycaemia across the risk quartiles, demonstrating that, as the risk
score increased, so did the rates of hypoglycaemia (Figures 1A and 2A).
In addition, the hypoglycaemia risk score was able to differentiate the
patient population into different quartiles of hypoglycaemia risk.
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Duration of diabetes (years) 10.1 ± 5.3 14.7 ± 7.2 17.3 ± 7.4 23.5 ± 9.3
Smoking status
Current 283 (15.0) 233 (12.3) 187 (9.9) 139 (7.4)
Previous 883 (46.8) 784 (41.5) 859 (45.5) 790 (41.9)
Never 721 (38.2) 870 (46.1) 841 (44.6) 958 (50.8)
Renal status
Normal renal function (eGFR
≥90 mL/min/1.73 m2 per
CKD-EPI)
522 (27.7) 409 (21.7) 335 (17.8) 213 (11.3)
Mild renal impairment (eGFR
60-89 mL/min/1.73 m2 per
CKD-EPI)
848 (44.9) 809 (42.9) 767 (40.6) 677 (35.9)
Moderate renal impairment (eGFR
30–59 mL/min/1.73 m2 per
CKD-EPI)
476 (25.2) 619 (32.8) 708 (37.5) 889 (47.1)
Severe renal impairment (eGFR
<30 mL/min/1.73 m2 per
CKD-EPI)
29 (1.5) 38 (2.0) 58 (3.1) 89 (4.7)
Hepatic impairment 24 (1.3) 40 (2.1) 64 (3.4) 68 (3.6)
Insulin naive 678 (35.9) 405 (21.5) 119 (6.3) 12 (0.6)
Trial eligibility stratum
Age ≥50 years and established
cardiovascular or chronic kidney
disease
1633 (86.5) 1548 (82.0) 1610 (85.3) 1644 (87.1)
Age ≥60 years and risk factors for
cardiovascular disease
248 (13.1) 334 (17.7) 272 (14.4) 239 (12.7)








BMI (kg/m2) 32.9 ± 6.5 33.1 ± 6.7 33.8 ± 7.0 34.6 ± 7.0
Systolic blood pressure (mmHg) 135.0 ± 17.0 135.2 ± 18.1 135.8 ± 18.7 136.2 ± 18.1
Diastolic blood pressure (mmHg) 78.4 ± 9.9 77.0 ± 10.1 75.6 ± 10.3 73.7 ± 10.6
Pulse (beats/min) 73.6 ± 11.5 73.4 ± 11.1 73.0 ± 11.1 72.3 ± 11.5
HbA1c (%) (mmol/mol) 8.1 ± 1.5 (65.5 ± 16.4) 8.4 ± 1.6 (68.5 ± 17.5) 8.5 ± 1.7 (69.5 ± 18.8) 8.6 ± 1.7 (71.0 ± 18.9)
Fasting plasma glucose (mmol/L)
(mg/dL)
9.2 ± 3.6 (166.0 ± 64.0) 9.4 ± 3.8 (169.9 ± 67.6) 9.7 ± 4.0 (174.7 ± 71.3) 9.8 ± 4.3 (176.2 ± 77.8)
eGFR (mL/min/1.73 m2) based on
CKD-EPI
74.4 ± 20.7 69.7 ± 21.0 66.5 ± 21.6 61.1 ± 20.6
Total cholesterol (mmol/L) (mg/dL) 4.2 ± 1.2 (161.2 ± 44.6) 4.3 ± 1.3 (167.5 ± 49.5) 4.2 ± 1.2 (163.5 ± 46.3) 4.4 ± 1.2 (168.2 ± 47.7)
LDL cholesterol (mmol/L) (mg/dL) 2.2 ± 0.9 (83.6 ± 35.2) 2.3 ± 1.0 (87.4 ± 37.5) 2.2 ± 0.9 (84.3 ± 35.9) 2.2 ± 1.0 (86.5 ± 37.2)
HDL cholesterol (mmol/L) (mg/dL) 1.1 ± 0.3 (41.5 ± 11.9) 1.2 ± 0.3 (44.5 ± 12.2) 1.1 ± 0.3 (43.8 ± 12.4) 1.2 ± 0.4 (47.7 ± 14.0)
Triglycerides (mmol/L) (mg/dL) 2.1 ± 1.7 (190.6 ± 152.8) 2.1 ± 1.9 (186.1 ± 171.3) 2.1 ± 1.6 (184.9 ± 140.7) 2.0 ± 2.0 (178.9 ± 174.5)
Data listed are number [proportion (%)] or mean ± standard deviation. Percentage refers to the proportion of patients within each risk quartile. Hepatic
impairment defined as having a score of >2 on a modified Child-Pugh criteria scale using only bilirubin and albumin values.
Abbreviations: BMI, body mass index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration formula; eGFR, estimated glomerular filtration rate;
HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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Patients in the very high-risk quartile were also those with the
highest observed incidence of MACE, as the incidence of MACE
increased with each increasing risk quartile (Figures 1B and 2B). A
similar trend was also observed for MACE and the individual MACE
components when applied to the LEADER trial data (Figure S1; see
Supporting Information).
Because of the size of the DEVOTE trial population and the fact
that the hypoglycaemia risk score was based on baseline data, randomi-
zation was maintained. All baseline parameters were well balanced
between the two arms in all four quartiles. This allowed for a fair treat-
ment comparison within each quartile (Table S2; see Supporting Infor-
mation). In all four quartiles, degludec was associated with risk ratios <1
for severe hypoglycaemia versus glargine U100, in line with the overall
DEVOTE analysis, where the rate ratio was 95% confidence interval
(CI) 0.60 (0.48; 0.76) (Figures 1A and 2A). The incidences of MACE and
all-cause mortality increased with each increasing risk quartile overall
and for both treatment arms, demonstrating that those patients with
the highest risk of severe hypoglycaemia had the highest incidences of
MACE and all-cause mortality (Figures 1B,C and 2B,C). In the very
high-risk quartile, the rate ratio (degludec vs. glargine U100) with regard
to severe hypoglycaemia was 95% CI 0.56 (0.39; 0.80). In this risk quar-
tile, the estimated risk of experiencing MACE was lower with degludec
versus glargine U100 [hazard ratio 95% CI 0.76 (0.58; 0.99)]. The effect
of a reduced rate of severe hypoglycaemia on MACE with degludec as
compared with glargine U100 diminished in the lower risk quartiles,
where the rates of hypoglycaemic events were notably lower.
4 | DISCUSSION
By using the hypoglycaemia risk score, developed from DEVOTE
baseline data, it was possible to identify patients with T2D who were
at high risk of severe hypoglycaemia. With each increasing risk quar-
tile, the incidences of severe hypoglycaemia, MACE and all-cause
mortality increased. In addition, those patients identified as having the
highest risk of severe hypoglycaemia appeared to have a higher inci-
dence of MACE and all-cause mortality, which is consistent with other
studies.4–6,24
F IGURE 1 Risk of outcomes: A,
severe hypoglycaemia, B, MACE and C,
all-cause mortality by severe
hypoglycaemia risk quartiles. MACE,
major adverse cardiovascular events
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In terms of the treatment arm comparisons, it is important to note
that the significantly lower rate of severe hypoglycaemia seen with
degludec compared with glargine U100 was reflected by a significantly
lower rate of MACE in the highest risk quartile, where patients had the
most events (both severe hypoglycaemia and MACE); albeit with a similar
proportion of patients, compared with the other quartiles, aged ≥50 years
with established cardiovascular or chronic kidney disease. These results
did not appear to be confounded by the baseline information included in
the risk score, as the patients' baseline characteristics across the four
quartiles, including the reduction in HbA1c levels and previous history of
cardiovascular disease, were similar between the risk quartiles, and there-
fore these factors do not confound the findings. The use of baseline infor-
mation in the analysis protected randomization and therefore the baseline
characteristics of patients allowed for the comparison of the treatment
effect. In addition, comparing the two treatments within each quartile was
equivalent to a standard subgroup comparison. The reduction in MACE in
parallel with the reduction in severe hypoglycaemia with degludec versus
glargine U100 supports but does not prove a causal link between these
events. While not conclusive evidence of a causal relationship, the results
from our study suggest that patients with high rates of hypoglycaemia are
also the patients with high MACE and mortality incidences.
In the absence of a specifically designed randomized controlled
trial comparing high or low rates of severe hypoglycaemia and its rela-
tion to MACE, which is neither ethical nor feasible, a direct causal link
between severe hypoglycaemia and adverse cardiovascular outcomes
cannot be demonstrated. Interestingly, results from a post-hoc analy-
sis of the LEADER trial have demonstrated a significantly higher risk
of MACE, cardiovascular death and non-cardiovascular death follow-
ing a severe hypoglycaemic event.10 In addition, the Outcome Reduc-
tion with Initial Glargine Intervention (ORIGIN) trial demonstrated
that severe hypoglycaemia was associated with an increased risk of
cardiovascular and all-cause death,4 while a post-hoc analysis of the
Action in Diabetes and Vascular Disease: PreterAx and Diamicron MR
Controlled Evaluation (ADVANCE) trial indicated that severe
hypoglycaemia was associated with higher risks of cardiovascular
events and death.5 However, a previous secondary analysis of
DEVOTE demonstrated the lack of an association between MACE
and a previous severe hypoglycaemic event, although a temporal
association with all-cause mortality and cardiovascular death and a
previous severe hypoglycaemic event was identified.9 It should be
noted that this previously reported DEVOTE analysis was limited by
the small proportion of patients who experienced a severe
F IGURE 2 Risk of outcomes: A,
severe hypoglycaemia, B, MACE and C,
all-cause mortality with degludec
vs. glargine U100 by severe
hypoglycaemia risk quartiles. CI,
confidence interval; glargine U100, insulin
glargine 100 units/mL; MACE, major
adverse cardiovascular events; PYO,
patient-years of observation
HELLER ET AL. 5
hypoglycaemic event before a MACE, making it difficult to establish a
significant difference, although the point estimate was aligned with
the above LEADER data.9,10 Overall, based on our results, and those
from other cardiovascular outcomes trials, we submit that it is most
likely that MACE, in the context of severe hypoglycaemia, are related
to both the underlying risk of MACE (vulnerability)25 and to conse-
quences of severe hypoglycaemia (causality).26
The analysis reported here has limitations. While DEVOTE included
a large number of patients at high risk of cardiovascular events, these
patients were selected for inclusion in a randomized trial setting and
may therefore not be representative of a real-world patient cohort. In
addition, DEVOTE only collected severe hypoglycaemic events, and
therefore the contribution of non-severe events, which have also been
shown to be associated with a higher risk of cardiovascular events, hos-
pitalization and all-cause mortality, could not be assessed.27,28 How-
ever, despite these limitations, we considered use of the DEVOTE
cohort relevant to these issues as it represents a population in whom
hypoglycaemia is of considerable concern.
Strengths of this analysis include use of a large, double-blind trial
with a high retention rate, independent adjudication of cardiovascular
and severe hypoglycaemic events, and use of a standard, robust defini-
tion of severe hypoglycaemia according to international guidelines.22
To allow the translation of the hypoglycaemia risk score to the clinical
setting, it was digitized into an online tool (http://www.hyporiskscore.
com/). This tool provides patients and health care providers with both
the level of risk of a patient experiencing a severe hypoglycaemic event
within 2 years and the observed risk of MACE within the risk quartile.
In conclusion, we demonstrated that the risks of MACE and all-cause
mortality appear to increase with the risk of severe hypoglycaemia,
supporting the known relationship between hypoglycaemia and cardiovas-
cular events. Furthermore, those patients with the highest hypoglycaemia
risk had a lower incidence of MACE with degludec compared with glargine
U100, in a patient population in whom degludec reduces the risk
of hypoglycaemia. These observations support the hypothesis that
hypoglycaemia is a risk factor for cardiovascular events.
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